BioSpace News Archive

BioMarin Pharmaceutical Inc. announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, October 26th, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a general business update.

Dyadic International, Inc. announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Barcelona, Spain.

ValGenesis Inc. successfully concluded its virtual annual user conference on Wednesday September 28th.

Wheeler Bio, a contract development and manufacturing organization specializing in small batch clinical production of biologics and GMP-grade reagents using their open-source platform, Portable CMC™, announced the first closing of their Series A financing round.

Arctoris Ltd, a tech-enabled biopharma platform company, has appointed three globally recognized experts in Alzheimer’s disease, Machine Learning applied to closed loop discovery, and automated chemistry as members of its Scientific Advisory Board: Professor John Davis, Professor Rafael Gómez Bombarelli, and Dr Teodoro Laino.

Terebellum announced a contractual partnership with NeurosolvTherapeutics, bringing its full suite of capabilities to support the launch of Perineline™, a new patented two-part therapy for spinal cord injuries developed by NeurosolvTherapeutics that has now attained EMA Orphan Designation and is expected to revolutionize the therapeutic treatment and resulting end patient outcomes from spinal cord injuries.

Bionomics Limited announced that it will be participating in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.

Saol Therapeutics announced that the pivotal Phase 3 clinical trial evaluating Sodium Dichloroacetate for the treatment of a rare, pediatric, ultra-orphan mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency has achieved its targeted enrollment.

ViewRay, Inc. announced that San Pietro Fatebenefratelli Hospital in Rome has treated its 1,000th patient with MRIdian® MRI-guided radiation therapy.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced participation in the following scientific and industry conferences in October: